Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 189 siguiente >>
Presentar resultados
Seleccionar todas
22.Enlace a cita original Cita con resumen
Wändell P, Carlsson AX, Holzmann M, Ärnlöv J, Johansson SE, Sundquist J, Sundquist K. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation - A cohort study in primary care. Eur J Clin Pharmacol 2017;73:febrero. [Ref.ID 101404]
23.Enlace a cita original Cita con resumen
Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, Vaccheri A, Motola D. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2017;83:1532-43. [Ref.ID 101351]
24. Cita con resumen
Sorigue M, Sarrate E, Orna E. Hemorragia intracraneal durante el tratamiento con apixabán. Med Clin (Barc) 2017;148:47-8. [Ref.ID 101342]
25.Tiene citas relacionadas Cita con resumen
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-1014. JAMA 2016;316:2115-25. [Ref.ID 100973]
26. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA 2016;176:1662-71. [Ref.ID 100958]
27. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh Y-H, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016:3 de octubre. [Ref.ID 100779]
28.Tiene citas relacionadas Cita con resumen
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-75. [Ref.ID 100609]
29. Cita con resumen
Gómez-Outes A, Lecumberri R. Antídotos de los nuevos anticoagulantes orales: realidad y expectativas. Med Clin (Barc) 2016;146:488-90. [Ref.ID 100372]
30. Cita con resumen
Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7. [Ref.ID 100280]
31. Cita con resumen
Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, Poli S, Kleinschnitz C, Steiner T, Heuschmann PU, Veltkamp R. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurology 2016;73:febrero. [Ref.ID 99784]
33.Tiene citas relacionadas Cita con resumen
Shin J-Y, Park M-J, Lee SH, Choi S-H, Kim M-H, Choi N-K, Lee J, Park B-J. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015;351:h3517. [Ref.ID 99249]
34. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu T-C, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64. [Ref.ID 98858]
35. Cita con resumen
Kuramatsu JB, Gemer ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Fleschsenhar J, Neugebauer H, Jüttler E, Grau A, Palm F, Röther J, Michels P, Hamann GF, Hüwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bäzner H, Roth A, Wöhrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Müllges W, Kraft P, Classen J, Hobohm C, Hom M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Günther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dörfler A, Köhmann M, Schwab S, Huttner HB. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;313:824-36. [Ref.ID 98820]
36. Cita con resumen
Hernández I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175:18-24. [Ref.ID 98726]
37. Cita con resumen
Hernández I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2014;175:18-24. [Ref.ID 98701]
39.Tiene citas relacionadas Cita con resumen
Steinberg BA. Refined bleeding estimates in adults starting anticoagulants. BMJ 2014;349:g4800. [Ref.ID 98176]
40. Cita con resumen
Anónimo. Treatment of atrial fibrillation. Med Lett Drugs Ther 2014;56:53-8. [Ref.ID 97926]
Seleccionar todas
 
<< anterior 21 a 40 de 189 siguiente >>